Core Insights - Virax Biolabs Group Limited has achieved ISO 13485:2016 and ISO 9001:2015 certifications for its quality management system, which are crucial for advancing regulated IVD development and U.S. clinical validation [1][4][5] Group 1: Certifications and Standards - ISO 13485:2016 certification pertains to the design and development of immunological assay components and kits for IVD applications, while ISO 9001:2015 covers the manufacturing, design, and development of research-use-only products and services [3][4] - These certifications establish a framework for design control, risk management, traceability, supplier qualification, and manufacturing consistency, thereby enhancing the operational foundation for the company's quality-managed development activities [4][7] Group 2: Strategic Implications - The certifications support the company's strategy to develop diagnostic technology for post-acute infection syndromes (PAIS), including Long COVID, and aim to build a T cell immune-profiling platform with a transatlantic clinical and regulatory footprint [5][9] - Strengthening quality systems is seen as essential for disciplined development and control of key assay components, which can facilitate validation activities and scale-up planning [7][8] Group 3: Clinical Validation Efforts - Virax is advancing its U.S. clinical validation work, supported by the strengthened quality framework, and has entered into a Research Services Agreement with Emory University's ADJUST Center to conduct clinical studies focused on immune profiling in individuals with Long COVID [6][8] - The collaboration with Emory aims to generate clinical data that will inform regulatory planning and potential future commercial rollout [6][8]

Core Viewpoint - Virax Biolabs is positioned for significant advancements in its proprietary diagnostic technology for post-acute infection syndromes (PAIS), including Long COVID, with a focus on achieving key clinical and operational milestones in 2026 [1][2] Company Developments - The company completed recruitment for its first UK clinical study (VRX-002) ahead of schedule, with initial data expected in Q2 2026 [1] - A second UK trial (VRX-003) in PAIS has been fully enrolled [1] - A clinical collaboration with Emory University has been established to support U.S. regulatory and commercial plans for Long COVID [1] - The ImmuneSelect research-use-only (RUO) portfolio is being developed to generate near-term revenue [1] Financial Position - As of September 30, 2025, the company held approximately $3.3 million in cash, with total assets of $5.7 million and no long-term debt, resulting in shareholders' equity of roughly $5.1 million [2] - The market capitalization is approximately $1.7 million, indicating that the market currently assigns limited value to the company's clinical programs and intellectual property [2] Strategic Priorities for 2026 - The primary focus is to deliver high-quality clinical data from the UK PAIS study and initiate U.S. clinical work with Emory University [2] - The company aims to expand its ImmuneSelect RUO portfolio and explore collaborations in vaccine response and oncology [2] - Continued engagement with regulatory bodies in both the UK and U.S. is planned to support the development of ViraxImmune™ [2]

Core Insights - Virax Biolabs Group Limited has signed a Research Services Agreement with Emory University's ADJUST Center to conduct clinical studies on ViraxImmune™, focusing on immune profiling in individuals with post-viral syndromes, particularly long COVID [1][2][3] - The collaboration aims to generate clinical data that will support regulatory submissions and potential commercial rollout of ViraxImmune™ [2][3] - The partnership is part of Virax's strategy to prepare for a pre-submission meeting with the FDA to discuss the regulatory pathway for ViraxImmune™ in PASC [3][4] Company Overview - Virax Biolabs is an innovative biotechnology company focused on immune response detection and diagnostics, particularly in viral diseases [5] - The company is developing T cell-based test technologies aimed at providing an immunology profiling platform, which is crucial for diagnosing post-viral syndromes like long COVID [5] Collaboration Significance - Partnering with Emory University, a leading institution in immunology and clinical research, is seen as a critical step in validating ViraxImmune™ in real-world patient populations [4][7] - The collaboration is expected to advance Virax's U.S. market entry strategy and create long-term value for shareholders [4]